Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
Estrella Immunopharma appointed Cynthia Pussinen as CEO and Chairperson of the Board, effective October 25, 2026, succeeding founder Cheng Liu. Dr. Liu moves to Chief Scientific Officer and continues as President and a board member, preserving continuity of the scientific leadership behind the ARTEMIS T-cell platform. Pussinen brings 30+ years of biotech leadership including CEO roles at Sernova and Ipsen Bioscience and a CTO post at Spark Therapeutics, with experience spanning cell and gene therapy development, commercialization, and capital formation.
Key figures
- Effective date
- October 25, 2026
- Aggregate peak sales supported
- $5 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.